Patient-derived 3D culture models enabling accurate efficacy testing of anticancer agents.

zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response. The ability of the zPREDICTA platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic.

Biotechnology

zPREDICTA

Mina Bissell

Robert Tressler

Amrita Krishnan

Karen Reckamp

Tom Kelly

The leadership team at zPREDICTA has a long history of experience in the field of oncology. The team has worked at many different companies, including Applied Silver, Inc., Predictive Oncology Inc, and zPREDICTA. They have also held positions at various universities, such as Purdue University and Cedars-Sinai. The team's experience and education makes them uniquely qualified to lead the company.

Leadership Team

CEO and Executive Team

Board of Directors

Leadership Team

About

Team members

Other teams at zPREDICTA

CEO and Executive Team

Board of Directors